株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ライム病:パイプライン製品の分析

Lyme Disease - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 200465
出版日 ページ情報 英文 33 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.37円で換算しております。
Back to Top
ライム病:パイプライン製品の分析 Lyme Disease - Pipeline Review, H2 2017
出版日: 2017年07月18日 ページ情報: 英文 33 Pages
概要

ライム病はマダニが媒介する細菌感染症であり、ボレリア・ブルグドルフェリという細菌によって引き起こされます。発疹、発熱、悪寒、疲労感、身体の痛みおよび頭痛といった症状があり、年齢、性別、地域がリスクファクターとなります。治療法は抗生剤の投与です。

当レポートでは、世界におけるライム病治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および彼らが開発中の製品のレビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

ライム病の概要

治療薬の開発

  • ライム病向けパイプライン製品:概要
  • ライム病向けパイプライン製品:比較分析

ライム病:開発中の治療薬:企業別

ライム病:開発中の治療薬:大学・研究機関別

ライム病:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

ライム病:開発中の製品:企業別

ライム病:開発中の製品:大学・研究機関別

ライム病:治療薬開発に従事している企業

ライム病:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

ライム病:最近のパイプライン動向

ライム病:休止中のプロジェクト

ライム病:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9545IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lyme Disease - Pipeline Review, H2 2017, provides an overview of the Lyme Disease (Infectious Disease) pipeline landscape.

Lyme disease is a bacterial infection transmitted by a tick. Lyme disease is caused by the bacterium Borrelia burgdorferi. Symptoms include rash, fever, chills, fatigue, body aches and headache. Risk factors include age, gender and geographic locations. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lyme Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Lyme Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lyme Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lyme Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 2, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Lyme Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Lyme Disease (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Lyme Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Lyme Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Lyme Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Lyme Disease (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Lyme Disease (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Lyme Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lyme Disease - Overview
    • Lyme Disease - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Lyme Disease - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Lyme Disease - Companies Involved in Therapeutics Development
    • LondonPharma Ltd
    • NovoBiotic Pharmaceuticals LLC
    • Valneva SE
  • Lyme Disease - Drug Profiles
    • azithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lyme disease vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lyme disease vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CRASP1 for Lyme Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Lyme Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Lyme Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VLA-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Lyme Disease - Dormant Projects
  • Lyme Disease - Product Development Milestones
    • Featured News & Press Releases
      • Dec 09, 2016: Valneva Receives FDA and European Approvals to Start Clinical Testing of Lyme Disease Vaccine Candidate
      • Jul 12, 2016: European Investment Bank Grants Valneva a EU25 Million Loan to Fund R&D Activities
      • Mar 24, 2016: VALNEVA to present at the 16th World Vaccine Congress in Washington D.C.
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Lyme Disease, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Lyme Disease - Pipeline by LondonPharma Ltd, H2 2017
  • Lyme Disease - Pipeline by NovoBiotic Pharmaceuticals LLC, H2 2017
  • Lyme Disease - Pipeline by Valneva SE, H2 2017
  • Lyme Disease - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Lyme Disease, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top